增殖诱导配体在多发性骨髓瘤中的表达及临床意义(3)
| 第1页 |
参见附件。
[6] Kern C， Cornuel JF， Billard C， et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway[J]. Blood，2004，103： 679-688.
[7] Briones J， Timmerman JM， Hilbert DM，et al. BLyS and BLyS receptor expression in non-Hodgkin’s lymphoma[J]. Exp Hematol， 2002，30：135-141.
[8] Bonci D， Hahne M， Felli N，et al. Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis[J]. Blood，2004，104(10)：3169-3172.
[9] Winter O， Moser K， Mohr E，et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow[J]. Blood， 2010，116(11)：1867-1875.
[10] Dorota Lemancewicza， Lukasz Bolkunb， Ewa Jablonskac， et al. Evaluation of TNF superfamily molecules in multiple myeloma patients：Correlation with biological and clinical features[J]. Leukemia Research，2013，5(14)：1-5.
[11] Dillon S， Gross J， Ansell SM，et al. An APRIL to remember： novel TNF ligands as therapeutic targets[J]. Nat Rev，2006，5：235-246.
[12] Hendriks J， Planelles L， De Jong-Odding J，et al. Heparan sulphate proteoglycan binding promotes APRIL-induced tumor cell proliferation[J]. Cell Death Diff，2005， 12：637-648.
[13] Fragioudaki M， Tsirakis G， Pappa CA， et al. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma[J]. Leuk Res，2012，36(8)：1004-1008.
[14] Breitkreutz I，Raab MS，Vallet S，et al. Targeting MEK1/2 blocks osteoclast differentiation function and cytokine secretion in multiple myeloma[J]. Br J H aematol，2007， 139：55-63.
[15] Marco Guadagnoli， Fiona Kimberley， Uyen Phan， et al. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas[J]. Blood，2011， 69：2900-2905.
(收稿日期：2013-11-18)
您现在查看是摘要介绍页，详见PDF附件。